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Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). It is currently incurable and
treatment is largely limited to supportive care. Family history is associated with an increased risk of ALS, and many Mendelian
causes have been discovered. However, most forms of the disease are not obviously familial. Recent advances in human
genetics have enabled genome-wide analyses of single nucleotide polymorphisms (SNPs) that make it possible to study
complex genetic contributions to human disease. Genome-wide SNP analyses require a large sample size and thus depend
upon collaborative efforts to collect and manage the biological samples and corresponding data. Public availability of
biological samples (such as DNA), phenotypic and genotypic data further enhances research endeavors. Here we discuss a
large collaboration among academic investigators, government, and non-government organizations which has created a
public repository of human DNA, immortalized cell lines, and clinical data to further gene discovery in ALS. This resource
currently maintains samples and associated phenotypic data from 2332 MND subjects and 4692 controls. This resource should
facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms
of neurodegeneration in ALS.
Citation: Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH, et al (2007) Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative
Gene Discovery. PLoS ONE 2(12): e1254. doi:10.1371/journal.pone.0001254
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegen-
erative disease that causes paralysis. Presently, it is incurable and
rapidly progressive, with a mean survival of 4–5 years from onset
[1,2]. Approximately 10% of ALS cases are inherited in a
Mendelian fashion (Table 1), with the remainder of cases
apparently sporadic [3–13]. Generally, familial forms are clinically
and pathologically indistinguishable from sporadic forms [14].
It is suspected that the sporadic forms of neurodegenerative
disorders are caused by multiple genetic variants that individually
make relatively weak contributions to risk. Genome-wide associ-
ation scans have been proposed as a way to assess a large number
of cases and controls to discover genetics factors with weak
contributions to risk for disease. Recent advances in single
nucleotide polymorphism (SNP) genotyping and haplotype
mapping have made -genome-wide association (GWA) scans
feasible. The distribution of familial versus sporadic disease in ALS
is similar to other adult-onset neurodegenerative diseases such as
Parkinson’s disease and Age-related Macular Degeneration, in
which whole genome approaches have been successful [15–17].
Towards the goal of allowing whole genome technology to be
applied in gene discovery in ALS, we have developed a publicly
accessible national resource of biological samples linked to
individual phenotypic datasets; a subset of this collection has
already been associated with publicly posted genotypic data (via
the DbGaP database of genotype and phenotype, http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db = gap) [18].
Because ALS is predominantly sporadic, environmental triggers
may be involved in disease initiation. With a few exceptions
suggested in the literature, such as participation in professional
sports [19] and perhaps a history of smoking, no clear
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environmental risk factors have been identified for ALS, perhaps
because the triggers may act only in genetically susceptible
individuals. GWA studies to identify susceptibility are also useful in
evaluating the interaction between genetic risk factors and putative
environmental triggers, as long as adequate data on environmental
exposures and lifestyle are also collected. Apart from information
concerning smoking history, the current dataset collected on each
patient does not include detailed risk factor information. However,
there is scope for the dataset to be expanded in the future to
include these putative triggers.
METHODS
Description of the Collaboration
Although ALS is the most common MND, it is still a relatively rare
disease with an incidence of around 1.6 per 100,000 in the United
States [20]. Thus, collaboration is essential to obtain a sufficient
sample size to allow statistically meaningful genetic studies.
NINDS has created a DNA and cell line repository towards the
goal of creating large sample size collections to allow the study of
complex disease genetics. In 2004, ALS was added as one of the
diseases banked (along with Parkinson, Stroke, and Epilepsy, and
most recently, added in 2007, Tourettes). To facilitate complex
gene discovery in ALS, the NINDS Repository (under a contract
with Coriell Cell Repositories), in collaboration with The ALS
Association (ALSA), The Muscular Dystrophy Association (MDA)
and academic scientists from 62 centers across the United States,
developed a program for evaluation of individuals affected
with ALS, neurologically normal controls, and banking of their
blood samples and clinical data. This unique public-private
collaboration facilitated leverage of resources to develop this
collection broadly across the United States. Germane to the
success of the venture was the high level of interaction and
communication among the clinical groups regarding subject
evaluation, sample collection, and other aspects of the project.
This allowed standardization to be maximized and also main-
tained enthusiasm at the sites for a ‘‘living’’ project. This model is
likely to be useful for other researchers who are interested in to
collecting, banking and sharing DNA for gene discovery in rare
disorders as well as those considering banking other types of
biological material or data.
Many of the clinicians in this collaboration are members of the
ALS Research Group (ALSRG) [20]. The ALSRG is a group of
investigators whose stated mission is to advance basic and clinical
research of ALS. When NINDS invited applications for an
administrative supplement to ongoing National Institutes of
Health (NIH)-funded studies to support sample collection towards
gene discovery in neurological disorders (NOT-NS-03-016), the
ALSRG recognized the opportunity for a collaborative response
[20]. The contributions of the ALSRG have ‘added value’,
because the samples and data they submit are made available
immediately to the broader scientific community [21]. Investiga-
tors who had been collecting and banking samples as a part of the
overall NINDS -funded effort in ALS gene discovery prior to the
NOT-NS-03-016 initiative also have contributed to this effort
(JH,AS,BT).
RESULTS
Together, we have built a collection of DNA and cell line samples
from well-characterized cases and controls; this collection is made
publicly available to researchers while protecting the privacy of all
participants. Biomaterials from 2332 individuals with amyotrophic
lateral sclerosis (49% men, 51% women), as well as samples from
4692 neurologically normal control subjects are currently in the
collection as of September, 2007 (Additional data on subject
characteristics can be found in Appendix S1 D). Of note, all of the
samples and data collected in the ALSRG project were done
under an agreement for immediate release for research to all bona
fide researchers. Phenotypic data corresponding to samples are
also posted in the NINDS repository web-based catalogue (http://
ccr.coriell.org/Sections/Collections/NINDS/?SsId = 10). Addi-
tional samples and data will be released in the next several
months as they are processed for DNA and data cleaning. Samples
may be purchased individually or as pre-compiled panels/plates,
each consisting of 92 subjects. There are now six such panels of
individuals diagnosed with ALS (plate catalog numbers
NDPT025, NDPT026, NDPT027, NDPT028, NDPT029 and
NDPT030) and nine panels of neurologically normal control
subjects (plate catalog numbers NDPT002, NDPT009, NDPT019,
NDPT020, NDPT021, NDPT022, NDPT023, NDPT024 and
NDPT031).
Table 1. Loci Linked to Mendelian Causes of ALS.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gene name Locus Name Inheritance Mode Locus Selected References
Cu/Zn superoxide dismutase (SOD1) ALS1 AD 21q22.1 43
ALSIN ALS2 AR 2q33.1 40
Senataxin (SETX) ALS4 AD 9q34.13 3
Dyncatin (DCTN1) AD 2p13 4,5
Angiogenin (ANG) 14q11.1-q1.2 6
Microtubule associated protein tau (MAPT)* AD 17q21.1 45
ALS3 AD 18q21 14,41
ALS5 AD 15q15.1-q21.1 46
ALS6 AD 16q21 10
ALS7 AD 20p13 10
Vesicle associated protein B (VAPB) ALS8 AD 20q13.33 11
ALS-FTD AD 9q21-22 12
ALS-FTD AD 9p13.2-21.3 13
*Multi-system neurodegeneration dominated by fronto-temporal dementia.
AD=Autosomal Dominant. AR =Autosomal recessive.
doi:10.1371/journal.pone.0001254.t001..
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Peripheral blood samples were collected and all are processed to
produce EBV-transformed lymphoblastoid cell lines. The ability to
derive cell lines from banked blood specimens allows for broad
sharing as well as for gene expression studies in order to determine
the biological relevance of genetic discoveries and other follow-up
studies. Additionally, the availability of cell lines ensures a
perpetual source of DNA, which allows broad sharing to occur
across the scientific community.
It is expected that all genotypic data generated from analysis of
samples in this collection will also be made available through
dbGaP (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db = -
gap). Already, a first stage analysis using genome wide SNP
technology has been carried out using 276 samples of sporadic
ALS cases and 271 neurologically normal controls from this
collection effort [18]. Briefly 555 352 unique SNPs were assayed in
each DNA sample using the Illumina Infinium II HumanHap550
SNP chip. More than 300 million genotypes were produced in 547
participants and this genotyping data is in the process of being
posted to dbGaP, the NCBI hosted public database for genotyping
and phenotyping (as described in more detail below). It will be
linked from DbGaP to the NINDS Repository samples and vice
versa. While no single locus was identified as associated with an
increased risk of disease in that first stage analysis [18], these
genotyping data will add greatly to the value of this resource for
additional hypothesis generation.
DISCUSSION
Sufficient Sample Size to Address Complex Genetic
Risk
Recent technological advances in genomics coincide with
increasing recognition of the importance of very large cohorts
for studying complex genetic effects [22]. How many subjects are
needed for disease gene discovery in ALS? The answer to that
question depends on several factors, including genetic architecture
(number of genes, their effect size, and interactions with other
genes and environmental risk factors), potential disease heteroge-
neity (genetic and environmental), and proposed study design. It
has been estimated that, for a statistical power of 80%, GWA
requires ,3,000 samples and ,3,000 controls to discover alleles
with frequencies of .0.2 or ,0.8 that associate with disease at an
odds ratio of .1.3 [22]. Similarly, analyzing specimens from a
minimum of 2,000 cases and 2,000 controls should allow
identification of alleles with approximately a 1.5-fold or greater
relative risk. Currently, the NINDS Repository has achieved a
collection size consistent with this latter more conservative
estimate. To design a study capable of detecting gene-gene or
gene-environment interactions, the sample size required to
maintain power would be increased by at least 4-fold. Moreover,
replication of experimental findings depends upon the availability
of populations independent of the original cohort. Thus, there are
clear reasons for large collections of specimens, and for expanding
the NINDS Repository ALS collection in the future should that be
possible.
It should be emphasized, however, that even with recent
advances in genomics and bioinformatics, the number of subjects
needed cannot be precisely predicted.
This is because we do not know the number of loci involved in
ALS, whether rare or common alleles are more prevalent in terms
of conferring susceptibility, nor their allele frequency and
penetrance. This complexity is illustrated by the role of SOD1
in ALS susceptibility. There are SOD1 alleles that are inherited in
a Mendelian fashion with ALS [2,43]. These represent a small
minority of ALS cases [2]; however, there are SOD1 alleles that
confer susceptibility with incomplete penetrance [24–26]. Thus, a
single gene can contribute to ‘‘Mendelian’’ and ‘‘complex’’ genetic
causes of ALS. It is not surprising, therefore, that many diseases,
including ALS and other neurodegenerative disorders, have
multiple similar but not identical clinical profiles that may reflect
differences in underlying genetic causes. Finally, different genetic
causes may be distributed among sub-populations or strata defined
by gender, age of onset, site of onset, race or ethnicity, or even,
importantly, therapeutic responsiveness and survival. These strata
are potentially valuable classification variables, and it is likely that
the more stratified a population of subjects, the larger the sample
size needed for study [22].
Phenotyping
It is possible that sporadic ALS represents a number of biological
entities, with overlapping clinical features [27]. This, together with
the requirement to enroll thousands of subjects, means that clearly
defined phenotypic definitions, standardized data collection, and
rigorous data management are essential to a collaborative effort
such as this one [27]. Detailed phenotypic data will be germane to
further analyses as well, as there are likely endo-phenotypes not yet
known to be biologically important but which are critical for
understanding complex disease. Furthermore, excellent clinical
assessment in the field maximizes information gained from these
collections, and avoids ‘‘wasted efforts’’ which can occur in
underpowered studies [28]. Fortunately, in the ALS academic
community, clinical trials networks have facilitated the use and
application of standardized clinical criteria, such that collection of
large, well-characterized populations in ALS for gene discovery is
achievable.
While ALS is the most common form of motor neuron disease,
other less common motor neuron and systemic diseases can
confound a diagnosis of ALS. Current diagnostic criteria for ALS
are based on clinical assessments, and require the presence of both
upper motor neuron (UMN-spasticity, hyper-reflexia, Babinski)
and lower motor neuron (LMN muscle atrophy, fasciculations,
weakness) involvement [27,29]. The level of diagnostic certainty
rests on the extent of UMN and LMN signs. These signs, their
severity, and associated findings form the basis of the World
Federation of Neurology (WFN) El Escorial diagnostic criteria
[27,30]. Per these criteria, ‘‘Definite ALS’’ is based on the
coexistence of UMN signs and LMN signs in the bulbar and spinal
regions. These criteria may not be fulfilled on an initial visit to the
clinic and thus longitudinal follow-up may be needed to reach an
accurate clinical diagnosis [31]. Such follow-up is possible in the
cohort collected here because of the data-basing capabilities of the
NINDS Repository as well as the patient management of the
ALSRG, and is ongoing for this collection. Additionally, since
clinical collection sites for the ALS collection are primarily led by
specialists in ALS, the specimens included in the NINDS DNA
and Cell Repository have highly accurate clinical data.
For subject inclusion, complete NINDS Repository Clinical
Data Elements (CDEs) are required. These elements were
developed to permit researchers using the specimens to apply
the El Escorial Criteria for the diagnosis of ALS at more than one
level of stringency in a standardized fashion [26,27,29]. Addition-
ally, these were designed towards allowing broad pooling of
multiple sample sets, since there are many international groups
collecting samples for ALS gene discovery with which those from
this effort could ultimately be pooled to achieve larger sample sizes
and thus greater power to detect genes of risk. These CDEs also
query exclusionary features, such as electrophysiological, CSF,
imaging or other findings suggestive of confounding diagnoses
(Appendix S1, B). Data dictionaries have been designed by the
ALS Gene Discovery
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collaboration (EK, KB) and are publicly available to allow rapid
referencing of all phenotypic terms (http://ccr.coriell.org/Sec-
tions/Collections/NINDS/CDE/mnd_dd.aspx?PgId = 347). This
further enhances the value of the biological specimens, guides
future submissions, and facilitates phenotype-genotype correla-
tions and sharing across collections.
In addition to precise and detailed phenotyping of affected
individuals, well-designed collections of unaffected (control)
subjects are crucial to genome-wide association studies of ALS
and other disorders. The phenotypic data collected on individual
controls in this collection is designed for use in gene discovery
efforts in ALS as well as other neurodegenerative disorders. CDEs
for unaffected individuals likewise were designed towards stan-
dardization, providing some neuro-psychiatric, medical and family
history assessments (Appendix S1, C). For example, all subjects,
whether case or control, are queried regarding family history of
ALS, Parkinsonism, dementia, Alzheimer’s disease, and other
neurological disorders. Identifying and enrolling large numbers of
control subjects in these studies benefits from having a large
collaborative team effort. This is valuable since ‘‘apparently
healthy’’, ‘‘neurologically normal’’ individuals, who would be
suitable for use as control subjects, are not routinely seen in an
academic neurology practice. This approach to using controls for
multiple studies has recently been shown to be valuable for gene
discovery. Using a shared set of ,3,000 controls, case-control
comparisons were used to successfully identify independent
significant association signals in bipolar disorder, coronary artery
disease, Crohn’s disease, rheumatoid arthritis, type 1 diabetes, and
type 2 diabetes [32]. That study supports our strategy of building a
carefully assessed shared control group represents a scientifically
sound and highly effective approach to GWA analyses of multiple
disease phenotypes.
There are some caveats resulting from this approach to control
collection. First, restrictions of enrollment (i.e., absence of a
medical or first degree family history of neuro-psychiatric disorder)
can slow recruitment. Second, it is not simple to classify a subject
as ‘‘free of neurological disease’’ since most control subjects are
evaluated only once, and neurological disease symptoms may arise
late in life. Finally, and perhaps most importantly, ALS patients
were recruited regardless of whether there was a family history of
neurological disease, while controls were not included if they had a
family history of neurological disease. This restriction was put in
place in order to facilitate broad sharing of control samples across
neurological disease entities. However, for optimal WGA studies it
can be argued that it is important to include only ALS probands
that do not have a family history of another neurological diagnosis.
To address this concern DNA panels being designed by the
Repository for WGA ALS studies for high throughput screening
from this collection segregate ALS cases with a family history of
neurological disease from those with no family history.
Consent and Patient Protection
Patient consent and privacy in genetic studies is an evolving field of
science policy. When the collaboration was established, care was
taken to assure compliance with existing regulations, while
planning for the potential of broad usage. In all cases the
collection, storage, distribution and use of human specimens and
data were conducted in accordance with all applicable regulations
including: 45 CFR Part 46: the FDA human subjects regulations
21 CFR Parts 50, 56, and 812: the Health Insurance Portability
and Accountability Act (HIPAA) Privacy and Security Rules (45
CFR Parts 160 and 164): and any state and local laws. Under 45
CFR Part 46, research use of specimens and data that are not
identifiable, and for which there are no links to individually
identifying information, is not considered to be human subject
research. Because individual identifiers are not accepted into the
public database, the data being shared are not considered human
subject data. Additionally, some repositories, including the
NINDS Repository, are operated under contracts to non-billable
entities, i.e., entities that do not provide clinical care. In those
cases, the Health Insurance Portability and Accountability Act
(HIPAA) does not apply. Nonetheless, this project and all others at
the NINDS Repository maintain HIPAA compliance towards the
goal of consistent, stringent respect for individual privacy (see
http://privacyruleandresearch.nih.gov/research_repositories.asp
and OHRP: Guidance on Research Involving Coded Private
Information or Biological Specimens, issued August 10, 2004
http://www.hhs.gov/ohrp/humansubjects/guidance/cdebiol.pdf).
In following the requirements for human subject research,
subject ascertainment and sample and data collection prior to
repository submission requires informed consent and oversight by
an Institutional Review Board (IRB). Obtaining informed consent
is a crucial element for assuring that individuals are aware of the
relative risks and benefits of the research and that they are free to
choose or refuse to participate [33]. The risks to participants
include potential breach of privacy and confidentiality. While the
data are systematically de-identified in terms of traditional
identifiers, genotyping could theoretically be used to identify an
individual were that person to provide a second sample to a third
party for comparison. There are also minor physical risks related
to blood drawing, such as bruising and discomfort at the site of
phlebotomy. While it is highly unlikely that any individual will
suffer from a psychosocial standpoint as a result of participating,
there is the putative risk that if individuals with ALS as a whole are
identified as having a particular gene variant, some might
experience stress in this regard.
The relative benefits to society are considered explicitly in
discussions with subjects. In the informed consent process for this
study, it is stressed that in a period of months to years this work is
unlikely to lead to direct benefit for any individual human subject,
but over many years to decades it may improve our understanding
ALS and ultimately result in health benefits for ALS patients.
Counter to negative speculation regarding anxiety and resistance
to participate in genetics studies, we anecdotally found that
subjects were extremely enthusiastic to participate. In fact, patients
and family members of those with ALS continue to request
participation (KAG). However, such requests cannot typically be
met, because this particular project was funded under an NINDS
initiative (NOT 03-016) which has expired, and so, the ALSRG is
not currently banking ALS samples in an ongoing fashion.
Nonetheless, NINDS continues to fund gene discovery projects
in ALS, and those other projects which are investigator initiated
(R01) funded projects continue to bank ALS samples as part of
those studies. It is hoped that additional large scale, ongoing
sample collections can be resumed, once it is clear that even larger
sample sizes are necessary and will be further used in gene
discovery.
All samples were collected using consent forms approved by
local IRBs. The NINDS repository has developed a sample
consent form (http://ccr.coriell.org/Sections/Support/NINDS/
icmodel.aspx?PgId = 317) based on the parameters suggested by
Beskow et al [33] and updated based on the discussions at a recent
NIH workshop, ‘‘Multi-Institute Symposium on the Application of
Genomic Technologies to Population-Based Studies’’ (June 2006
internal NIH meeting, KG personal communication). This
template offers a useful starting point for investigators developing
consent forms for genetic studies in ALS and many other
disorders. Additionally, the NINDS Repository suggests specific
ALS Gene Discovery
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elements for consent forms to assure that key points are raised
(Appendix S1, E). Stemming from that, and because this collection
was established in collaboration with a clinical trials network
(ALSRG), an IRB protocol and template was developed by the
ALSRG that allowed relatively uniform and coordinated IRB
approval processes for all participating sites [21].
Often, longitudinal follow-up of individuals suspected of having
ALS is needed to reach an accurate diagnosis. However, patient
protections make collection of longitudinal data difficult for a
centralized repository; as such follow-up data must be collected
without breaking subject anonymity. Therefore, longitudinal data
collection depend on the voluntary submission of such data by
contributing investigators, which was approved by most local IRBs
and is described in these consent forms.
Processing of samples submitted to the NINDS
Repository
Limited access to biomaterials collected by individual laboratories
and projects has presented a major roadblock in the past to
genome-wide analyses of complex diseases, including gene
discovery in sporadic ALS. The NIH and other contracting
agencies have addressed the need for such biomaterials by funding
non-profit repositories to receive, manage and distribute human
biomaterials, including the NINDS Repository. Over the last 30
years, the Coriell Institute has played a leading role in establishing
quality control guidelines for Cell and DNA DNA repositories.
A key process in the Coriell repositories relies on an approach
that was developed over 30 years ago, in which EBV infects and
transforms B lymphocytes present in whole blood [33]. The
transformed lymphoblasts from each individual subject represent a
renewable source of genetic material. Both immortalized cell lines
and the DNA derived from them are a valuable resource for the
biomedical research community at large. Additionally, in some
cases, availability of cell lines with associated genotypic and
phenotypic information represents a second-generation resource
for mRNA- and protein-expression analyses and other cell-based
studies aimed at follow-up of genetic ‘‘hits’’.
The Coriell Institute has established a set of quality control
procedures to ensure that each sample is processed in an identical
manner and with the same high standards.
Coriell Cell Repositories have established a set of quality control
procedures to ensure that each sample is processed in an identical
manner and with the same high standards. For the NINDS
Repository, two tubes containing blood samples are submitted per
subject. Each blood sample is assayed for length polymorphism at
6 independent short tandem (STR) repeat loci. As a first level of
control, the STR profiles from the two blood tubes must be
identical to each other. Moreover, all derived biospecimens, i.e.
DNA and cell culture, must also match the STR profile from the
original blood. Gender is determined by a PCR assay, and is
compared with declared gender. Finally, Coriell uses STR profiles,
gender, and year of birth to establish singularity for each
submission, thus avoiding banking the same subject twice under
different catalog numbers. Care is taken to ensure that identical
twins are not eliminated by this process.
Advances in Genomic Medicine
Technical advances in molecular biology over the past 20 years,
including the advent of polymerase chain reaction (PCR), discovery
of SNPs, and automation have provided essential tools for high-
throughput genome-wide studies. Population-based maps of the
correlations among SNPs (linkage disequilibrium) are being
developed in an ongoing fashion [34]. The human genome is
thought to contain at least 10 million SNPs, about one in every 300
bases. Theoretically, researchers could hunt for genes using a map
listing all 10 million SNPs, but there are major practical drawbacks
to that approach, including expense and data management.
Fortunately, the HapMap project has accelerated disease related
gene discovery as well as many other projects [35]. HapMap has
identified blocks of cis-linked SNPS that, in a given ethnic
population, generally segregate as a group. This allows researchers
to use a few ‘tag SNPs’ to identify a unique block of the genome (a
haplotype block). As a result, rather than needing to sequence all 10
million SNPs in the human genome, only 300,000 to 600,000 tag
SNPs are needed to efficiently identify the haplotypes in the human
genome [36]. Already, this approach is finding widespread use in fine
mapping of genetic disorders, in the delineation of genetic influences
in multifactorial diseases such as breast cancer, myocardial
infarction, type 2 diabetes, and asthma, and as genetic markers to
predict responses to drugs and adverse drug reactions [37].
Performing whole genome association (WGA) scans in ALS, as
well as in other disorders, depends on robust technologies for
analysis of individual SNP variants. Several SNP genotyping
platforms exist, and the use of more than one in gene discovery
should have the added benefit of comparing these alternative
platforms.
Bioinformatics
Broad access to data and biomaterials is one of the key principles
in realizing the potential of genomic science [38]. Underpinning
uniform public access are bioinformatics solutions for managing
the phenotypic and genotypic data. The NINDS Repository was
the first bio-repository to make disease-related, genome-wide
genotyping data completely and publicly accessible (in Parkinson’s
disease and Control subjects, see references [16,38]). This
genotype/phenotype dataset (https://queue.coriell.org/Q/
snp_index.asp), initially posted in March 2006, and now also
available via dbGaP (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db = gap) has generated considerable interest in the scientific
community, and has already been accessed by about a thousand
different researchers across the globe. This underscores the value
of public availability of this data.
Such bioinformatics solutions are dependent on the existence of
a scalable and extensible informatics infrastructure. The informa-
tion management system should meet the requirements of real-
time data capture, collection site management, chain of custody
handling, and operational efficiency for a large number of samples,
each of which is linked to individual data. Moreover, as an
integrated solution, the system must manage the genotypic and
phenotypic data associated with bio-specimens under compliance
with all relevant privacy laws. The information systems design
must not only consider the quality but also the accessibility of the
bio-specimens and associated data. The system also needs to have
the ability to integrate with other databases as both a source and a
recipient of data. The NINDS Repository bioinformatics system
meets all of these requirements as does the National Center for
Biotechnology Information (NCBI)’s dbGaP project.
DbGaP meets all of these requirements on a broader scale by
providing analysis and retrieval resources for many types of data,
including genetic and other biological data. Furthermore, it
provides a standardized approach for public sharing of anon-
ymized genotype and phenotype data across NIH. This broadly
available, standardized, and scalable resource prevents redundan-
cies and allows uniform approaches to privacy and access [40,41].
The ALS study phenotypic data, data dictionary, and supporting
documents are soon to be posted on the dbGaP site (http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db = gap). DbGaP has two
ALS Gene Discovery
PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1254
orders of access (open, and controlled) which permit broad release
of non-sensitive data in the first case, but also providing oversight
and investigator accountability for sensitive data sets involving
personal health information in the second. Summaries of the ALS
and control subject CDEs, the ALS data dictionary, and other
documents used for this collection and analyses will be made
available to investigators via dbGaP. It is expected that
investigators who use the bio-specimens banked at the NINDS
repository for future genotyping will submit their genotyping data
to dbGaP once it is available. The dbGaP database links to the
database at the NINDS that also has searchable phenotypic data
and associated biological materials which would allow sub-set
analysis and biological expression study follow-up of ‘hits’.
Summary
ALS research has entered an era of discovering complex genetic
causes of disease. Many genes in familial ALS have been identified
or mapped. However, most cases of ALS are sporadic, and genetic
factors may contribute to the risk for disease. WGA studies are
feasible given the advances in SNP and other genotyping
technologies. However, to carry WGA forward with adequate
power to detect true effects, a very large sample size is needed–
probably thousands of unique affected subjects and thousands of
controls. It is clear that bio-repositories play an important role in
this effort, as do bioinformatics resources, clinical consortia, and a
willingness to share data broadly. NINDS has succeeded in
creating a resource containing thousands of unique DNA and
immortalized cell line samples from individuals with ALS and
corresponding control subjects. The strong tradition of clinical
collaboration in ALS set the foundation for building this biological
sample bank and phenotypic dataset which now allows whole
genome studies in ALS to occur. This effort was based upon a
collaboration comprised of academic investigators, NIH staff,
clinicians, and non-government organizations to create an
infrastructure by which biomaterials and associated phenotypic
and genotypic data which have been collected can be distributed
responsibly with minimal barriers to researchers. Bioinformatics
development at the NINDS Repository has allowed organization
of searchable phenotypic data and sample sets, and integrates with
other database projects, such as NCBI’s DbGaP. A first stage
WGAS analysis has been undertaken with a subset of these
samples, which will facilitate further hypothesis generation and
genetic study of this and other sample collections.
As with all genome-wide approaches to complex disease, there
are continued challenges regarding determination of optimal
sample sizes for affected and control populations. There is no
single paradigm for gene discovery and no single ideal study design
or analytical approach. Additional sample sets may be needed for
validation of initial studies both in the same populations as well as
in other ethnic groups. We anticipate that the identification of
disease-specific genes will provide opportunities to develop early
diagnostic measures, suggest surrogate markers of disease
progression, and supply targets for therapeutic discovery. In
summary, the NINDS Repository in collaboration with dbGaP
allows genotype, phenotype, and biological specimens to be
associated and distributed as a public resource. Future studies will
likely explore gene-gene and gene environment interactions. The
inclusion of pharmacological response or significant drug exposure
in future clinical datasets of patients enrolled in genetic studies
with further enrich this collection. Our experience can act as a
springboard for such future endeavors.
SUPPORTING INFORMATION
Appendix S1
Found at: doi:10.1371/journal.pone.0001254.s001 (0.38 MB
DOC)
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